ClinicalTrials.gg
CompletedNCT05381025Updated Oct 13, 2022

Kavalactones on Sleep and Cortisol in Healthy Special Forces Trainees

An interventional study of Kava (Piper methysticum) extract in Sleep, sponsored by Thorne HealthTech, Inc. Completed at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-13.

Sponsored by Thorne HealthTech, Inc · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

This research study is being done to better understand the effects of kava supplementation on sleep quality and salivary cortisol in the context of the acute physical and psychological stress of military special forces preparation training. Kava is a botanical dietary supplement derived from the plant Piper methysticum. Cortisol is a hormone associated with stress.

Read the detailed description

Acute physical and behavioral stress can interfere with sleep quality and cause cortisol to increase. This can have a negative impact on quality of life and the ability to perform optimally.

Kava, derived from the rootstumps of the Piper methysticum plant, has been utilized traditionally, socially, and for its calmative properties by the peoples of Oceania for millennia. Kava has been available as a dietary supplement for decades.

Participants in this placebo-controlled cross-over study will be enrolled concurrently with a special operations prep class during which they will be experiencing significant physical and mental stressors. Participants will be divided into two arms - one taking kava and the other taking placebo for the first two-week phase of the study. Following a washout and cross-over, participants will switch what they are taking for the second two-week phase.

02

Conditions studied

  • Sleep

Keywords

  • Sleep
  • Kava
  • Piper methysticum
  • Stress
  • Cortisol
  • Special Operations
03

In context

Lead sponsor

Thorne HealthTech, Inc is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • Provides consent to participate in the study
  • Understands and agrees to follow all study procedures and limitations

Exclusion criteria

Exclusion Criteria:

  • Female
  • Use of kava within the past 8 weeks
  • Use of over the counter or prescription sleep aids including dietary supplements within the past 8 weeks
  • Use of acetaminophen that cannot be discontinued or replaced with an NSAID during the study
  • Known liver disease or dysfunction
  • Known kidney disease or dysfunction
  • Any prior adverse reaction or known sensitivity or allergy to kava or related botanicals (peppers)
  • Recent history of clinical depression or anxiety diagnosis
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Active to Placebo (Cohort 1)

    Participants randomly allocated to Cohort 1 for Phase 1 will begin the study taking the active ingredient and will cross-over to taking placebo in Phase 2 of the study after a washout period.

    Dietary Supplement: Kava (Piper methysticum) extract

  • Experimental
    Placebo to Active (Cohort 2)

    Participants randomly allocated to Cohort 2 for Phase 1 will begin the study taking the placebo and will cross-over to taking the active ingredient in Phase 2 of the study after a washout period.

    Dietary Supplement: Kava (Piper methysticum) extract

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Salivary Cortisol - Phase 1

    Diurnal salivary samples will be collected and tested for cortisol levels \[ng/ml\].

    Time frame: Day 1 and 15

  2. Change in Salivary Cortisol - Phase 2

    Diurnal salivary samples will be collected and tested for cortisol levels \[ng/ml\].

    Time frame: Day 1 and 15

  3. Change in Sleep Latency, Duration, and Quality - Phase 1

    Data from the Restorative Sleep Questionnaire-Weekly (RSQ-W) \[Total score 0-100; higher indicates better restorative sleep\] plus other selected sleep questions will be combined to assess participant sleep during the study.

    Time frame: Day 1, 8, and 15

  4. Change in Sleep Latency, Duration, and Quality - Phase 2

    Data from the Restorative Sleep Questionnaire-Weekly (RSQ-W) \[Total score 0-100; higher indicates better restorative sleep\] plus other selected sleep questions will be combined to assess participant sleep during the study.

    Time frame: Day 1, 8, and 15

Secondary outcomes

  1. Change in General Mood - Phase 1

    Data from the Depression, Anxiety, and Stress Scale-21 (DASS-21) \[Total score 0-63; higher is more distressed\] will be used non-diagnostically to generate comparative scores which will be analyzed against the cortisol findings to assist in the interpretation of the kava-related outcomes.

    Time frame: Day 1, 8, and 15

  2. Change in General Mood - Phase 2

    Data from the Depression, Anxiety, and Stress Scale-21 (DASS-21) \[Total score 0-63; higher is more distressed\] will be used non-diagnostically to generate comparative scores which will be analyzed against the cortisol findings to assist in the interpretation of the kava-related outcomes.

    Time frame: Day 1, 8, and 15

  3. Change in Motivation and Volition - Phase 1

    Data from the Cravings for Rest and Volitional Energy Expenditure Scale (CRAVE) \[Total score 0-50; higher is more motivated\] will be used to assess participant motivation to perform in the context of the strenuous and demanding training schedule of this Prep Class.

    Time frame: Day 1, 8, and 15

  4. Change in Motivation and Volition - Phase 2

    Data from the Cravings for Rest and Volitional Energy Expenditure Scale (CRAVE) \[Total score 0-50; higher is more motivated\] will be used to assess participant motivation to perform in the context of the strenuous and demanding training schedule of this Prep Class.

    Time frame: Day 1, 8, and 15

07

Study locations

1 site
  • Performance First
    Virginia Beach, Virginia 23453, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Jul 2022, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 19, 2022
StartActual
May 11, 2022
Primary completionActual
Jul 1, 2022
CompletionActual
Oct 9, 2022
Last update
Oct 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05381025
Lead sponsor
Thorne HealthTech, Inc
Collaborators
Performance First
Responsible party
Sponsor
First posted
May 19, 2022
Start date
May 11, 2022
Primary completion
Jul 1, 2022
Completion
Oct 9, 2022
Last update
Oct 13, 2022

Study contacts

Michael A Schmidt, PhD, MPhil
principal investigator · Advanced Pattern Analysis & Countermeasures Group

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Piper methysticum root

Start the discussion